Last reviewed · How we verify
MDI Epinephrine
Epinephrine is a sympathomimetic amine that activates alpha and beta adrenergic receptors to increase heart rate, blood pressure, and airway dilation.
Epinephrine is a sympathomimetic amine that activates alpha and beta adrenergic receptors to increase heart rate, blood pressure, and airway dilation. Used for Anaphylaxis (acute allergic reaction), Severe asthma exacerbation with bronchospasm.
At a glance
| Generic name | MDI Epinephrine |
|---|---|
| Also known as | MDI Adrenaline |
| Sponsor | Children's Hospital of Eastern Ontario |
| Drug class | Sympathomimetic amine / Catecholamine |
| Target | Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Emergency Medicine / Allergy & Immunology |
| Phase | Phase 3 |
Mechanism of action
Epinephrine binds to alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors on target tissues. This activation increases cardiac contractility and heart rate (beta-1), causes vasoconstriction (alpha-1), and promotes bronchial smooth muscle relaxation (beta-2). In anaphylaxis, these combined effects rapidly reverse airway obstruction, hypotension, and cardiovascular collapse.
Approved indications
- Anaphylaxis (acute allergic reaction)
- Severe asthma exacerbation with bronchospasm
Common side effects
- Tremor
- Tachycardia
- Palpitations
- Anxiety
- Headache
- Hypertension
Key clinical trials
- Bronchiolitis in Infants Placebo Versus Epinephrine and Dexamethasone Study (PHASE3)
- Treating Exacerbations of Asthma With Oral Montelukast in Children (PHASE2)
- Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma (PHASE2)
- Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008) (PHASE3)
- Pharmacokinetics (PK) Study of Epinephrine Inhalation Aerosol in Healthy Volunteers (PHASE1, PHASE2)
- Evaluation of Efficacy and Safety of E004 in Children With Asthma (PHASE3)
- Randomized, Placebo/Active Crossover Dose-ranging Study for Safety and Efficacy in Asthma Patients. (PHASE1, PHASE2)
- Epinephrine Inhalation Aerosol USP, a HFA-MDI Study for Assessment of Pharmacokinetics (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |